Clinical trial
Routine Clinical Practice in Spain: Evaluation of the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment (PREVAIL Study)
NCT03828045 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Routine Clinical Practice in Spain: Evaluation of the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment (PREVAIL Study)
- Lead sponsor
- Amgen
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 6, 2019
- Completion date
- October 20, 2021
- Enrollment
- 119 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.